Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseasesPratteln, Switzerland, July 1, ...

Treating Duchenne muscular dystrophy before symptoms emerge may improve motor function, clinical trial suggests

At Binghamton University, researchers were among the first to find ways to help patients with Duchenne muscular dystrophy ...

Improving growth outcomes for children living with dwarfism

New findings from a trial conducted at Children's Hospital Colorado (Children's Colorado) and University of Colorado (CU) ...

DWP confirms full list of 178 conditions that could qualify for PIP payments

The Department for Work and Pensions (DWP) has confirmed the 178 conditions that qualify individuals for Personal Independence Payments (PIP). More than four million people were claiming PIP as of ...
The Lancet

Muscular dystrophies

cNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA dDubowitz Neuromuscular Centre ...